You are here: Industry Insights > Alexion

News List

Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder drugs
June 28, 2019
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder.
Jazz, Alexion and Lundbeck to pay $122m to settle kickback probe pharmaceutical-technology
April 09, 2019
Drugmakers Jazz Pharmaceuticals, Lundbeck and Alexion Pharmaceuticals have agreed to pay a total of $122.6m to settle allegations of paying kickbacks via copay assistance foundations.
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases pharmafocusasia
March 21, 2019
Alexion Pharmaceuticals, Inc and Zealand Pharma A/S today announced a collaboration to discover and develop novel peptide therapies for complement-mediated diseases. Peptides offer a number of advantages, including being highly selective and potent, allo
Alexion aims for fourth rare disease use for blockbuster Soliris pharmaphorum
February 27, 2019
The FDA has granted a fast review for Alexion Pharmaceuticals’ filing for its Soliris, as a treatment for a rare neurological disease that leads to worsening disability, blindness, paralysis, and possibly early death.
Alexion runs toward big Ultomiris goals with early Soliris switching success fiercepharma
February 24, 2019
Alexion has big goals for Soliris follow-up Ultomiris in paroxysmal nocturnal hemoglobinuria (PNH), and wooing patients over from predecessor Soliris is key. But so far, executives say, those aims are right on track.
Alexion joins with Dicerna to develop RNAi therapies for complement diseases pharmaphorum
December 20, 2018
Alexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused by problems in the complement system.
M&As this week: Alexion Pharmaceutical, OvaScience americanpharmaceuticalreview
November 10, 2018
Following the transaction, Syntimmune will add its clinical-stage drug candidate SYNT001 to Alexion’s portfolio.SYNT001 is a humanised monoclonal antibody (mAb) that is currently being evaluated in Phase Ib/IIa studies.
Alexion snaps up another biotech, paying $1.2B for Syntimmune fiercebiotech
September 28, 2018
Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune.
Alexion to acquire Syntimmune biospectrum
September 27, 2018
The deal gives Alexion clinical-stage anti-FcRn antibody SYNT001 with potential to address a number of rare IgG-mediated diseases
Alexion's Soliris almost entirely eliminates relapses in rare neuromyelitis optica spectrum disorder pharmafile
September 27, 2018
Alexion has revealed new Phase 3 findings for Soliris (eculizumab), showing the drug met its primary endpoint in the treatment of anti-aquaporin-4 (AQP4)...

Previous page 1 2 3 4 5 Next page